about
The neutrophil-lymphocyte ratio and its utilisation for the management of cancer patients in early clinical trials.PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate.Tumor clone dynamics in lethal prostate cancerSerial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug AdministrationAdvantages of one step nucleic acid amplification (OSNA) whole node assay in sentinel lymph node (SLN) analysis in breast cancerFirst-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer.Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses.Management of patients with castration-resistant disease.Molecular alterations and emerging targets in castration resistant prostate cancer.Circulating tumor cells: a multifunctional biomarker.Molecular characterization and clinical utility of circulating tumor cells in the treatment of prostate cancer.Switching and withdrawing hormonal agents for castration-resistant prostate cancer.What have we learned from exceptional tumour responses?: Review and perspectives.Volume of Bone Metastasis Assessed with Whole-Body Diffusion-weighted Imaging Is Associated with Overall Survival in Metastatic Castration-resistant Prostate Cancer.Effect on Overall Survival of Locoregional Treatment in a Cohort of De Novo Metastatic Prostate Cancer Patients: A Single Institution Retrospective Analysis From the Royal Marsden Hospital.Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents.Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use.Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer.A Joint Model for the Kinetics of CTC Count and PSA Concentration During Treatment in Metastatic Castration-Resistant Prostate Cancer.Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate CancerTumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone.Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer.Reply: 'Comment on Anti-tumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer'.Visceral disease in castration-resistant prostate cancer.Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma.Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents.Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot Study.An internally validated new clinical and inflammation-based prognostic score for patients with advanced hepatocellular carcinoma treated with sorafenib.Neutrophil to Lymphocyte Ratio in Castration-Resistant Prostate Cancer Patients Treated With Daily Oral Corticosteroids.CCR 20th Anniversary Commentary: Circulating Tumor Cells in Prostate Cancer.Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional SurveyProgressive computed tomography (CT) appearances preceding malignant spinal cord compression (MSCC) in men with castration-resistant prostate cancerExternal Validation of a Prognostic Model Predicting Overall Survival in Metastatic Castrate-resistant Prostate Cancer Patients Treated with AbirateroneReply to: Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate resistant prostate cancerAntitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abirateroneA randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancerMultimodality Treatment of Pediatric and Adult Patients With Ewing Sarcoma: A Single-institution ExperienceEnzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis
P50
Q35274955-EAD079B1-1E37-48AF-86E6-5F2C53170A54Q35540013-7DB9E68C-6D92-4E1E-B87B-E261B869F044Q35575930-D5D51C77-AF59-475D-AE61-EA44D612EE57Q36087929-7E72BD37-D014-42E3-A5E9-92DC05453C2FQ37299755-14C57FD6-50B9-4E8F-A845-293950BF83FAQ37323018-A92F836B-F578-419E-B032-C49E62A9A33DQ37462283-0ADA7D44-8774-4F66-9C02-5A703285436AQ38159746-F6A510BA-5FA3-4024-B9C1-BDBC0B9A8B66Q38177996-9AF8B3C9-89DE-43A7-AFAE-8A46ADE7D33FQ38211963-4A8E70D2-E27F-432D-AF9C-1F3CF3A8F502Q38214294-746F520F-7C3D-4B60-BEB4-285E8E4DBF3AQ38309205-22FCE824-F3FF-4DFA-BA2C-2AD84699E306Q38391815-5A296F51-60CF-4250-8ACD-52630F8E3B15Q38710656-303D94C6-7EF4-418B-891B-9AD465F15F16Q38750276-CF1F5830-0717-4848-B7DA-9F459D59CFB8Q38905865-BE8E3490-A009-4945-B758-C7025FFE4AC7Q39189394-0ED3B1A2-4123-4171-BB9F-284C72E9B40CQ39819392-9CD3BADC-463E-4A28-99F4-EAC0DBA9BDF9Q39930469-9F1AE5B0-9991-4393-BB36-2AD3E4CC3CEEQ40678942-F10CD08A-F18D-4CDE-B5C8-56F31D8F25BFQ41496288-F1549795-E671-491C-9CA2-9CF0882A0A93Q42586178-2BC57B23-A136-43BC-B53E-42CC832D264AQ42641870-B7942661-ED13-4DB7-A555-3BE813C9D96EQ42748594-54674C80-63F1-48D1-BF32-5A5829A98E0FQ42758807-14AE9095-D675-4B35-B628-81EE6621DA23Q47169813-97F8417C-7D17-4BCE-A5DB-FB23A80AE183Q47931535-54EA9985-E4DD-4BE1-8D1D-E330FDC5814FQ48205685-9B54B9D0-0989-43FF-AF7D-BB5E6FF3A685Q48250035-0B8B14AC-253C-4B04-855C-0828FFA6A721Q50588643-984C1462-C248-4CA1-AEEC-4A5D37FDB7BBQ53284550-16AAABE5-4ADD-4CFA-AC39-35015603C502Q57539286-FFF945C4-1D3E-4F60-B24E-5AEFE2D36ECDQ57693877-0182CA89-016D-4B46-8AB1-C4CB23B74AFEQ57693891-B356326B-2912-4D29-B9E4-E59CCD6F449DQ57693902-AB3263A0-9F67-48D7-9CD8-5426DEA9E2EAQ57693906-7434F8A9-4321-4219-B6ED-9BBE24C5F5D8Q86132975-52C3B894-295F-40CD-8678-726A0142F129Q87221816-BF580CD1-4C30-4E65-9909-E70498E5B7E0Q87535893-D99EB8FC-7541-4903-B0E3-857549EE74A8
P50
description
researcher (ORCID 0000-0001-7550-0657)
@en
name
David Lorente
@en
type
label
David Lorente
@en
prefLabel
David Lorente
@en
P108
P108
P31
P496
0000-0001-7550-0657